tiprankstipranks
Advertisement
Advertisement

HRTX Stock Latest News

Heron Therapeutics Faces Nasdaq Minimum Bid Price Deficiency
Company AnnouncementsHeron Therapeutics Faces Nasdaq Minimum Bid Price Deficiency
6d ago
8K
HRTX
Heron Shareholders Approve Directors, Incentive Plans, Tax Measures
PremiumCompany Announcements
Heron Shareholders Approve Directors, Incentive Plans, Tax Measures
15d ago
8K
HRTX
X4, TripAdvisor, Heron, DigitalOcean, Shake Shack Trending
PremiumWeekend Updates
X4, TripAdvisor, Heron, DigitalOcean, Shake Shack Trending
26d ago
DOCN
HRTX
Heron Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
PremiumThe Fly
Heron Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
29d ago
HRTX
Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents
PremiumCompany Announcements
Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents
29d ago
8K
HRTX
Heron Therapeutics downgraded at Needham after Cinvanti patents invalidated
PremiumThe FlyHeron Therapeutics downgraded at Needham after Cinvanti patents invalidated
29d ago
HRTX
Heron Therapeutics downgraded to Hold from Buy at Needham
Premium
The Fly
Heron Therapeutics downgraded to Hold from Buy at Needham
29d ago
HRTX
Heron announces U.S. district court decision regarding Cinvanti patents
Premium
The Fly
Heron announces U.S. district court decision regarding Cinvanti patents
30d ago
HRTX
Heron Therapeutics Faces Tight Covenant Constraints That Threaten Liquidity and Strategic Flexibility
PremiumCompany Announcements
Heron Therapeutics Faces Tight Covenant Constraints That Threaten Liquidity and Strategic Flexibility
2M ago
HRTX
Heron Therapeutics Signals Recovery Despite Soft Q1
PremiumCompany Announcements
Heron Therapeutics Signals Recovery Despite Soft Q1
2M ago
HRTX
Heron Therapeutics price target lowered to $4 from $6 at H.C. Wainwright
PremiumThe Fly
Heron Therapeutics price target lowered to $4 from $6 at H.C. Wainwright
2M ago
HRTX
Heron Therapeutics reports Q1 EPS (4c), consensus (2c)
PremiumThe Fly
Heron Therapeutics reports Q1 EPS (4c), consensus (2c)
2M ago
HRTX
Heron Therapeutics backs FY26 revenue view $173M-$183M, consensus $174.73M
PremiumThe FlyHeron Therapeutics backs FY26 revenue view $173M-$183M, consensus $174.73M
2M ago
HRTX
HRTX Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
HRTX Earnings this Week: How Will it Perform?
2M ago
HRTX
Heron Therapeutics (HRTX): Buy Rating on Expanding Hospital Product Adoption and Attractive Risk‑Reward
Premium
Ratings
Heron Therapeutics (HRTX): Buy Rating on Expanding Hospital Product Adoption and Attractive Risk‑Reward
3M ago
HRTX
Heron Therapeutics Strengthens Executive Contracts Amid Strategic Focus
PremiumCompany Announcements
Heron Therapeutics Strengthens Executive Contracts Amid Strategic Focus
3M ago
8K
HRTX
Heron Therapeutics Signals Profitable Growth After Strong Quarter
PremiumCompany Announcements
Heron Therapeutics Signals Profitable Growth After Strong Quarter
4M ago
HRTX
Heron Therapeutics: Profitable Growth Outlook and Acute Care Momentum Underpin Buy Rating and $3 Target
PremiumRatings
Heron Therapeutics: Profitable Growth Outlook and Acute Care Momentum Underpin Buy Rating and $3 Target
4M ago
HRTX
Heron Therapeutics reports Q4 EPS (2c) vs 2c last year
PremiumThe Fly
Heron Therapeutics reports Q4 EPS (2c) vs 2c last year
4M ago
HRTX
Heron Therapeutics sees FY26 revenue $173M-$183M
PremiumThe FlyHeron Therapeutics sees FY26 revenue $173M-$183M
4M ago
HRTX
HRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
HRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
4M ago
HRTX
Heron Therapeutics: Undervalued Growth Story Driven by Zynrelef and Aponvie Momentum
Premium
Ratings
Heron Therapeutics: Undervalued Growth Story Driven by Zynrelef and Aponvie Momentum
6M ago
HRTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >